Novartis is folding activities of its Cell and Gene Therapy unit into other business and research locations, eliminating 120 positions, the Swiss drugmaker said on Wednesday. The move intensifies a corporate makeover begun this year as it focuses on high-growth areas including cancer immunotherapy.
Swiss drug maker Roche Holding said its cancer immunotherapy Tecentriq (atezolizumab) had helped people, diagnosed with a specific type of lung cancer, live significantly longer compared with chemotherapy in a Phase III study.
22:53 LG Display reports record fourth quarter profit of $778 million17
19:39 $1M '100 percent Swiss Made' watch made of real Swiss cheese16
11:20 PE firm Warburg buys $121 million stake in Indian cinema operator PVR16
04:18 NAB, Oxley to sell stakes in Cambridge Industrial manager to e-Shang Redwood17